Old Web
English
Sign In
Acemap
>
authorDetail
>
Benjamin M. Beckermann
Benjamin M. Beckermann
Hoffmann-La Roche
Medicine
Interim analysis
Myeloid leukemia
IDASANUTLIN
Cytarabine
3
Papers
24
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Emicizumab Prophylaxis in Persons with Mild or Moderate Hemophilia A: Results from the Interim Analysis of the HAVEN 6 Study
2021
Blood
Claude Negrier
Johnny Mahlangu
Michaela Lehle
Pratima Chowdary
Olivier Catalani
Victor Jiménez Yuste
Benjamin M. Beckermann
Christophe Schmitt
Cédric Hermans
Giuliana Ventriglia
Jerzy Windyga
Anna Kiialainen
Roseline dOiron
Paul Moorehead
Vanda Teodoro
Amy D. Shapiro
Johannes Oldenburg
Show All
Source
Cite
Save
Citations (0)
MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine +/- idasanutlin in relapsed or refractory acute myeloid leukemia.
2020
Future Oncology
Pau Montesinos
Benjamin M. Beckermann
Olivier Catalani
Jordi Esteve
Katia Gamel
Marina Konopleva
Giovanni Martinelli
Annabelle Monnet
Cristina Papayannidis
Aaron Park
Christian Recher
Rebeca Rodríguez-Veiga
Christoph Röllig
Norbert Vey
Andrew Wei
Sung-Soo Yoon
Pierre Fenaux
Show All
Source
Cite
Save
Citations (24)
Contribution of Idasanutlin Exposure to Safety, Pharmacodynamics and Clinical Response of Patients with Acute Myeloid Leukemia Treated with Idasanutlin + Cytarabine in Phase I and III Studies
2020
Blood
Candice Jamois
Doreen Anders
Benjamin M. Beckermann
Magali Genevray
Kirsten Mundt
Claire Petry
Joy Yang
Nastya Kassir
Christophe Schmitt
Show All
Source
Cite
Save
Citations (0)
1